ACE-031 vs Hexarelin.

ACE-031 (ramatercept) is not a peptide but a recombinant fusion protein that joins the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc region of IgG1. Developed by Acceleron Pharma, it works as a ligand trap that soaks up myostatin and related TGF-beta-family proteins that normally restrain muscle growth. It was engineered as a candidate therapy for muscle-wasting conditions, most prominently Duchenne muscular dystrophy (DMD). Unlike most compounds grouped with muscle peptides, it genuinely reached human clinical trials before its development was stopped.

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS), structurally derived from the GHRP-6 family of growth hormone-releasing peptides. It is an investigational compound that was studied in the 1990s and 2000s as a potential agent for probing and stimulating growth hormone secretion and, separately, for direct effects on the heart. It is not an approved drug.

ActRIIB is a receptor through which myostatin (GDF-8), activins, and several other TGF-beta-superfamily ligands signal to limit skeletal muscle mass. By presenting a soluble decoy receptor, ACE-031 binds these ligands in the circulation and prevents them from activating ActRIIB on muscle, releasing the brake on muscle growth. Because the trap captures multiple ligands beyond myostatin, including some that act on blood vessels, it produces effects outside muscle as well. This mechanism was established in animal models and then probed directly in humans.

Hexarelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same pituitary/hypothalamic receptor activated by the natural hormone ghrelin. Receptor binding engages Gq/11-phospholipase C signaling, mobilizing intracellular calcium in pituitary somatotrophs and triggering pulsatile growth hormone release; this pathway is distinct from and synergistic with GHRH, and also opposes somatostatin tone. Hexarelin additionally binds CD36, a scavenger receptor expressed in cardiac and vascular tissue, which is the proposed basis for GH-independent cardiovascular effects observed in animal models. Because it is a non-selective secretagogue, it also stimulates ACTH/cortisol and prolactin release to a greater degree than more selective agents.

ACE-031 has genuine human data. Attie et al. reported a single ascending-dose study in healthy postmenopausal women in Muscle & Nerve (2013, PMID 23169607), observing increases in lean mass and biomarker changes consistent with myostatin inhibition. That was a phase 1 design: a small, single-administration, dose-escalating study in a narrowly selected healthy population, sponsored by the developer Acceleron Pharma, with imaging and biomarker endpoints rather than measures of function, and without the duration needed to detect anything that emerges over months. Campbell et al. published the randomized, placebo-controlled trial in ambulatory boys with DMD in Muscle & Nerve (2017, PMID 27462804), which showed trends toward preserved 6-minute-walk distance, higher lean mass and bone mineral density, and lower fat mass, but was stopped early. Because the trial was terminated before completing enrollment and follow-up, the walking-distance result remained a trend rather than a demonstrated benefit, the study lost the statistical power it had been designed with, and no confirmatory trial was ever run. Every efficacy statement about ACE-031 therefore rests on an interrupted study. This places ACE-031 well beyond the preclinical status of most muscle compounds, even though it never demonstrated confirmed clinical efficacy. The wider myostatin-pathway field has repeated the same pattern. Domagrozumab, an anti-myostatin antibody, failed its primary endpoint in Duchenne muscular dystrophy. Bimagrumab, an ActRII-blocking antibody, has produced consistent increases in lean mass without delivering the functional outcomes originally sought, and its cardiac safety has been examined separately in older adults (PMID 41873146). Increasing muscle mass has proven considerably easier than improving what patients can actually do. For ACE-031 specifically there is no chronic exposure data, no published long-term follow-up of the participants who were treated, no completed outcome trial, and no development activity after the early 2010s from which to draw further evidence.

Human data exist but are limited to small, short-term, acute physiology studies rather than outcome trials. Acute intravenous hexarelin reliably raised serum growth hormone in healthy volunteers and was compared head-to-head with GH in a controlled human study (Imbimbo/Ghigo group, J Endocrinol Invest 1999, PMID 10342360). Separate small studies reported short-lasting increases in left ventricular ejection fraction and cardiac output in normal subjects, GH-deficient patients, and dilated-cardiomyopathy patients, effects that appeared GH-independent (Bisi/Broglio et al., Endocrine 2001, PMID 11322491). A chronic-administration study found that GH responses desensitized over weeks and characterized effects on the pituitary-adrenal axis and prolactin (Clin Endocrinol 1999, PMID 10341859). Most cardioprotection evidence (CD36-mediated ischemia/reperfusion protection, IL-1 signaling) is preclinical and rodent-based (e.g., Int Heart J 2017, PMID 28321024; review J Geriatr Cardiol 2014, PMID 25278975); none of this advanced to a successful human cardiac outcome trial, and clinical development was discontinued.

The DMD program was halted in 2011 for safety reasons. Investigators observed dose-related, non-muscle vascular effects, specifically epistaxis (nosebleeds), gum bleeding, and telangiectasias (small dilated skin vessels), attributed to the trap's activity on additional TGF-beta-family ligands. The mechanistic explanation is that a soluble ActRIIB decoy does not bind myostatin alone: it also sequesters activins and bone morphogenetic proteins that help maintain vascular integrity, so the bleeding signal is a predictable consequence of the trap's breadth rather than an idiosyncratic reaction. These events appeared in children being treated for a serious progressive disease, the population most willing to accept risk for benefit, and they were still judged unacceptable. Acceleron and its partner Shire ended the collaboration and did not restart development. Short-term human exposure is documented, but the compound was discontinued precisely because of these off-target vascular signals, and long-term safety was never established. There is no chronic dosing data, no published long-term follow-up of the boys who were exposed, and no immunogenicity or reproductive toxicology in the public record. Later programs targeting the same pathway were deliberately engineered for narrower ligand selectivity in order to avoid this exact problem. Anything sold online under the ACE-031 name is an unapproved recombinant protein produced outside pharmaceutical manufacturing controls, where identity, glycosylation, aggregation state, and endotoxin content are all unverified, and aggregated Fc-fusion proteins carry their own immunogenicity risk. The monitoring a real trial would demand, including vascular and bleeding assessment, dermatologic examination, and anti-drug antibody testing, does not exist outside a clinical setting.

Documented effects in human studies include hexarelin's lack of GH selectivity: it raises cortisol, ACTH, and prolactin alongside growth hormone, so it does not produce a clean GH signal. A well-described limitation is rapid tachyphylaxis/desensitization, with attenuated GH responses on repeated or continuous dosing demonstrated both in vitro (second-messenger level) and over weeks of human administration. Long-term safety in humans is essentially unknown because no large or extended trials were completed; chronic GHS-driven IGF-1 elevation raises theoretical concerns common to this class (fluid retention, insulin sensitivity changes, and the general caution that growth-promoting signaling could be undesirable in the setting of malignancy), but these are not established for hexarelin specifically. There is no established safety profile for non-clinical/self-administered use.

ACE-031 was never approved by the FDA or any other regulator, and its clinical development was terminated in the early 2010s after the DMD trial was stopped for safety. It is not a marketed drug and is not legitimately available for human use. Any product sold online as ACE-031 is unapproved research-grade material.

Hexarelin is investigational and has never received FDA or EMA marketing approval; its clinical development was discontinued. It is prohibited in sport at all times by WADA as a growth hormone secretagogue / GH-releasing peptide under category S2 of the Prohibited List, and it is generally sold only as a research-use-only chemical.